Vijaya L. Korlipara

Dr. Vijaya L. Korlipara


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
NGNehaben A. Gujarati
Nehaben A. Gujarati
LZLeli Zeng
Leli Zeng
PGPranav Gupta
Pranav Gupta
Zhe-Sheng ChenZhe-Sheng Chen
Zhe-Sheng Chen
VKVijaya L. Korlipara
Vijaya L. Korlipara

1 November 2017 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
ARAireen A. Romu
Aireen A. Romu
ZLZining Lei
Zining Lei
BZBin Zhou
Bin Zhou
Zhe-Sheng ChenZhe-Sheng Chen
Zhe-Sheng Chen
VKVijaya L. Korlipara
Vijaya L. Korlipara

1 September 2012 in Biochemical Pharmacology
Verified
Journal Article
Closed access
YKYe-Hong Kuang
Ye-Hong Kuang
JPJay P. Patel
Jay P. Patel
KSKamlesh Sodani
Kamlesh Sodani
CWChung-Pu Wu
Chung-Pu Wu
LLLi-Qiu Liao
Li-Qiu Liao
Zhe-Sheng ChenZhe-Sheng Chen
Zhe-Sheng Chen

Verified
Journal Article
Open access
PDF file
SNSilpa Narayanan
Silpa Narayanan
NGNehaben A. Gujarati
Nehaben A. Gujarati
Jing-Quan WangJing-Quan Wang
Jing-Quan Wang
ZWZhuo-Xun Wu
Zhuo-Xun Wu
JKJagadish Koya
Jagadish Koya
Zhe-Sheng ChenZhe-Sheng Chen
Zhe-Sheng Chen
The overexpression of ATP-binding cassette transporter, ABCG2, plays an important role in mediating multidrug resistance (MDR) in certain types of cancer cells. ABCG2-mediated MDR can significantly attenuate or abrogate the efficacy of anticancer drugs by increasing their efflux from cancer cells. In this study, we determined the efficacy of the novel benzamide derivative, VKNG-2, to overcome MDR due to the overexpression of the ABCG2 transporter in the colon cancer cell line, S1-M1-80. In vitro, 5 μM of VKNG-2 reversed the resistance of S1-M1-80 cell line to mitoxantrone (70-fold increase in efficacy) or SN-38 (112-fold increase in efficacy). In contrast, in vitro, 5 μM of VKNG-2 did not significantly alter either the expression of ABCG2, AKT, and PI3K p110β protein or the subcellular localization of the ABCG2 protein compared to colon cancer cells incubated with the vehicle. Molecular docking data indicated that VKNG-2 had a high docking score (-10.2 kcal/mol) for the ABCG2 transporter substrate-drug binding site whereas it had a low affinity on ABCB1 and ABCC1 transporters. Finally, VKNG-2 produced a significant concentration-dependent increase in ATPase activity (EC50 = 2.3 µM). In conclusion, our study suggests that in vitro, VKNG-2 reverses the resistance of S1-M1-80, a cancer cell line resistant to mitoxantrone and SN-38, by inhibiting the efflux function of the ABCG2 transporter.

30 January 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
CCChaoyun Cai
Chaoyun Cai
QTQiuxu Teng
Qiuxu Teng
MMMegumi Murakami
Megumi Murakami
SASuresh V. Ambudkar
Suresh V. Ambudkar
Zhe-Sheng ChenZhe-Sheng Chen
Zhe-Sheng Chen
VKVijaya L. Korlipara
Vijaya L. Korlipara
A series of twenty-two quinazolinamine derivatives showing potent inhibitory activities on breast cancer resistance protein (BCRP) and p-glycoprotein (P-gp) were synthesized. A cyclopropyl-containing quinazolinamine 22 was identified as a dual BCRP and P-gp inhibitor, while azide-containing quinazolinamine 33 showed BCRP inhibitory activity. These lead compounds were further investigated in a battery of mechanistic experiments. Compound 22 changed the localization of BCRP and P-gp in cells, thus inhibiting the efflux of anticancer drugs by the two ATP-binding cassette (ABC) transporters. In addition, both 22 and 33 significantly stimulated the ATP hydrolysis of the BCRP transporter, indicating that they can be competitive substrates of the BCRP transporter, and thereby increase the accumulation of mitoxantrone in BCRP-overexpressing H460/MX20 cells. Azide derivative 33, exhibited a greater inhibitory effect on BCRP after UV activation and can serve as a valuable probe for investigating the interactions of quinazolinamine derivatives with BCRP. Notably, the dual BCRP and P-gp inhibitors 4–5, 22–24, 27, and BCRP inhibitor 33 showed improved metabolic stability compared to Ko143.

17 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
SNSilpa Narayanan
Silpa Narayanan
YFYing-Fang Fan
Ying-Fang Fan
NGNehaben A. Gujarati
Nehaben A. Gujarati
QTQiuxu Teng
Qiuxu Teng
Jing-Quan WangJing-Quan Wang
Jing-Quan Wang
Zhe-Sheng ChenZhe-Sheng Chen
Zhe-Sheng Chen
The emergence of multidrug resistance (MDR) to chemotherapeutic drugs is a major problem in the therapy of cancer. Knowledge of the mechanisms of drug resistance in cancer is necessary for developing efficacious therapies. ATP-binding cassette (ABC) transporters are transmembrane proteins that efflux chemotherapeutic drugs from cancer cells, thereby producing MDR. Our research efforts have led to the discovery of VKNG-1, a compound that selectively inhibits the ABCG2 transporter and reverses resistanctabe to standard anticancer drugs both in vitro and in vivo. VKNG-1, at 6 µM, selectively inhibited ABCG2 transporter and sensitized ABCG2-overexpressing drug-resistant cancer cells to the ABCG2 substrate anticancer drugs mitoxantrone, SN-38, and doxorubicin in ABCG2-overexpressing colon cancers. VKNG- 1 reverses ABCG2-mediated MDR by blocking ABCG2 efflux activity and downregulating ABCG2 expression at the mRNA and protein levels. Moreover, VKNG-1 inhibits the level of phosphorylated protein kinase B (PKB/p-AKT), and B-cell lymphoma-2 (Bcl-2) protein which may overcome resistance to anticancer drugs. However, the in vitro translocation of ABCG2 protein did not occur in the presence of 6 µM of VKNG-1. In addition, VKNG-1 enhanced the anticancer efficacy of irinotecan in ABCG2- overexpressing mouse tumor xenografts. Overall, our results suggest that VKNG-1 may, in combination with certain anticancer drugs, represent a treatment to overcome ABCG2-mediated MDR colon cancers.